Antisten MB, 35 mg 60 pcs

A product that normalizes the energy metabolism of cells subjected to hypoxia or ischemia. It prevents reduction of intracellular ATP content, ensures normal functioning of membrane ion channels, transmembrane transport of potassium and sodium ions and preservation of cellular homeostasis.

Trimetazidine slows fatty acid oxidation through selective inhibition of long-chain 3-ketoacetyl-CoA thiolase, which leads to increased glucose oxidation and the restoration of conjugation between glycolysis and oxidative decarboxylation and has been shown to protect myocardium from ischemia. Switching fatty acid oxidation to glucose oxidation underlies the antianginal action of trimetazidine.

In experimental studies on animals it has been shown that trimetazidine maintains the energy metabolism of the heart and neurosensory organs during episodes of ischemia; it reduces the magnitude of intracellular acidosis and the degree of changes in the transmembrane ion flux that occurs during ischemia; Reduces the migration and infiltration of polynuclear neutrophils in ischemic and reperfused heart tissues, reduces the size of myocardial damage; while having no effect on hemodynamics.

Indications

Long-term therapy of coronary artery disease: prevention of angina attacks (monotherapy or as part of combination therapy); treatment of cochleo-vestibular disorders of ischemic nature (including dizziness, tinnitus, hearing impairment); chorioretinal vascular disorders with an ischemic component.

Pharmacological effect

A drug that normalizes the energy metabolism of cells exposed to hypoxia or ischemia. Prevents a decrease in intracellular ATP content, ensures the normal functioning of membrane ion channels, transmembrane transport of potassium and sodium ions and the preservation of cellular homeostasis.

Trimetazidine slows fatty acid oxidation by selectively inhibiting long-chain 3-ketoacetyl-CoA thiolase, resulting in increased glucose oxidation and restoration of the coupling between glycolysis and oxidative decarboxylation and has been shown to provide myocardial ischemia protection. The switch from fatty acid oxidation to glucose oxidation underlies the antianginal effect of trimetazidine.

Experimental studies in animals have shown that trimetazidine supports the energy metabolism of the heart and neurosensory organs during periods of ischemic episodes; reduces the amount of intracellular acidosis and the degree of changes in the transmembrane ion flow that occurs during ischemia; reduces the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfusion tissues of the heart, reduces the size of myocardial damage; it does not affect hemodynamics.

Special instructions

Trimetazidine does not affect the ability to drive a car or perform work that requires a high speed of psychomotor reactions.

Active ingredient

Trimetazidine

Composition

1 tab. trimetazidine dihydrochloride

Excipients:

hypromellose – 93 mg,

microcrystalline cellulose – 178.9 mg,

colloidal silicon dioxide – 1.55 mg,

magnesium stearate – 1.55 mg.

Film shell composition:

opadry II 85F240012 Pink (polyvinyl alcohol – 4 mg, macrogol 3350 – 2.438 mg, red iron oxide dye – 0.04 mg, yellow iron oxide dye – 0.022 mg, talc – 1.48 mg, titanium dioxide – 2.02 mg).

Contraindications

Pregnancy, lactation (breastfeeding), hypersensitivity to trimetazidine.

Side Effects

Possible: allergic reactions (including skin rash, itching).

Rarely: nausea, vomiting, gastralgia.

Overdose

Currently, no cases of drug overdose have been reported.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C. Protect from moisture.

Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Ozon, Russia